Peer Review History

Original SubmissionJuly 15, 2025
Decision Letter - Giacomo Di Filippo, Editor

PONE-D-25-37061 What Is the Significance of A New Breast Mass in Women Aged 40 or Above? A Cross-sectional Study PLOS ONE

Dear Dr. Eskandari,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 10 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Giacomo Di Filippo, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following financial disclosure:

“This study was supported by a grant from the Deputy of Research of Tehran University of medical Sciences, Tehran, Iran; Grant Number 1400-1-259-53034.”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript.

5. We note that you have indicated that there are restrictions to data sharing for this study. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Before we proceed with your manuscript, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see

https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.

We will update your Data Availability statement on your behalf to reflect the information you provide.

6. In the online submission form you indicate that your data is not available for proprietary reasons and have provided a contact point for accessing this data. Please note that your current contact point is a co-author on this manuscript. According to our Data Policy, the contact point must not be an author on the manuscript and must be an institutional contact, ideally not an individual. Please revise your data statement to a non-author institutional point of contact, such as a data access or ethics committee, and send this to us via return email. Please also include contact information for the third party organization, and please include the full citation of where the data can be found.

7. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

8. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

9. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments:

I believe the paper could use some refinement based on what the reviewer said. I also believe most of these issues are major in their nature.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This research report introduces a valuable attention to clinical factors (recency of mass) and in future this research will impact diagnostic decision-making and patient outcomes. It had its limitation which stated in discussion to be considered as well.

I only suggest revising in typos, punctuation, and double spaces as seen.

Reviewer #2: Dear authors, Thank you for this work; here are my comments for more clarity:

#Inconsistent Labeling of Protocols (P1 and P2): The methods section defines P1 as your center's protocol (considering recency) and P2 as the usual protocol (ignoring recency). However, the results, discussion, and Table 3 reverse this: Protocol 1 is labeled as "usual" (70.1% sensitivity, 95.4% specificity), and Protocol 2 as your center's (84.1% sensitivity, 40.3% specificity). This confusion could mislead readers and invalidate comparisons. Therefore, you should standardize labeling throughout. Use descriptive terms like "Recency-Inclusive Protocol" (your approach) and "Standard BI-RADS Protocol" (usual). Revise Table 3 footnotes accordingly. Recalculate if needed to confirm values—your sensitivity gain is a key selling point, so ensure accuracy.

# Methodological Clarity and Reproducibility: The "unwritten protocol" for biopsy decisions is vaguely described. For example, how was "new mass" defined (e.g., patient-reported vs. prior imaging comparison)? What thresholds were used for "suspicious clinical exam"? Abbreviations like BE (breast exam), MG (mammography), and US (ultrasound) are not defined on first use. Sample size justification is absent—was power calculated for detecting sensitivity differences? Please expand the methods to include a flow diagram of the protocol (e.g., as a supplementary figure). and define "new mass" explicitly (e.g., absent on prior imaging within 1 year). It's better to add a sample size calculation using tools like G*Power, assuming a 10-15% sensitivity difference (based on your results). If applicable report inter-rater reliability for BI-RADS assignments if multiple radiologists were involved. This will enhance reproducibility.

# Results Presentation and Interpretation: Table 1 shows gravidity differences (p<0.001), but the text misinterprets; higher gravidity (≥5) is more common in malignant cases (34.81% vs. 14.56%), yet you state "fewer pregnancies" for benign—correct this. No confidence intervals (CIs) for diagnostic metrics, limiting precision assessment. Please add 95% CIs to all metrics in Table 3 (e.g., sensitivity 84.1% [95% CI: 77.2-89.7%], calculated via binomial methods).

# References : Please update to include 2024-2025 publications

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

Revision 1

Dear Dr. Giacomo Di Filippo,

We sincerely appreciate the time and effort you and the reviewer have dedicated to evaluate our manuscript, "What Is the Significance of A New Breast Mass in Women Aged 40 or Above? A Cross-sectional Study" (Manuscript ID: PONE-D-25-37061). We are grateful for the constructive feedback, which has helped us improve the quality of our work.

We have carefully addressed all the comments and suggestions provided by the reviewer. Below, we provide a point-by-point response to each remark, detailing the revisions made in the revised manuscript. All changes have been highlighted in yellow.in the revised version for easy reference

Journal Requirements:

Comment 1: “comply with PLOS ONE's requirements”

Response 1: We ensured that the manuscript and files are formatted and named to meet all PLOS ONE style requirements.

Comment 2: “We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.”

Response 2: Unfortunately we couldn’t find where to edit ‘Financial Disclosure’ in the submission portal. Please consider the following as our funding and financial disclosure:

“This study was supported by a grant from the Deputy of Research of Tehran University of Medical Sciences, Tehran, Iran; Grant Number 1400-1-259-53034. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Comment 3: “Please state what role the funders took in the study.”

Response 3: We added the necessary statement to our financial disclosure and cover letter.

Comment 4: “Please note that funding information should not appear in any section or other areas of your manuscript.

Response 4: We removed the funding information from our manuscript.

Comment 5: “The data availability restrictions”

Response 5: The data that support the findings of this article are not publicly available due to ethical concerns observed in the instructions of the Arash Registry of Breast Diseases Protocol. They can be requested from bdrc@tums.ac.ir.

Comment 6: “The data contact point is a co-author, which violates policy; it must be a non-author institutional contact.”

Response 6: According to this policy, Arash Registry of Breast Diseases’ contact address (bdrc@tums.ac.ir.) is presented as the data contact person. This has been corrected in the manuscript.

Comment 7: “PLOS requires an ORCID iD for the corresponding author.”

Response 7: The corresponding author linked his ORCID ID in the submission portal. His orcid number is: 0000-0001-7988-3050

Comment 8: “Your ethics statement should only appear in the Methods section of your manuscript.”

Response 8: The ethics statement now only appears in the Methods section of our manuscript.

Editor:

We sincerely thank you for your time and valuable feedback.

Comment 1: “I believe the paper could use some refinement based on what the reviewer said. I also believe most of these issues are major in their nature.”

Response 1: The manuscript has undergone a comprehensive and detailed revision to address all the major concerns raised by the reviewers.

Reviewer #1:

We are truly grateful for your kind and encouraging words, and sincerely thank you for your comment.

Comment 1: "I only suggest revising in typos, punctuation, and double spaces as seen.”

Response 1: The manuscript has been proofread (both by Grammarly and by an expert in English), and all typographical errors, punctuation, and extraneous spacing have been corrected.

Reviewer #2

Thank you for taking the time to review our work. We’re grateful for your time and valuable feedback.

Comment 1: "Inconsistent Labeling of Protocols (P1 and P2)”

Response 1: We apologize for the mistakes. We have re-written all related parts and renamed the protocols as “our institutional protocol” and “the guideline-based protocol” to prevent errors.

Comment 2: "The "unwritten protocol" for biopsy decisions is vaguely described. For example, how was "new mass" defined (e.g., patient-reported vs. prior imaging comparison)? What thresholds were used for "suspicious clinical exam"?”

Response 2: The relevant explanations have been added in the Methods section (lines 119-131).

Comment 3: "Abbreviations like BE (breast exam), MG (mammography), and US (ultrasound) are not defined on first use.”

Response 3: All abbreviations have been defined upon their first use in the revised manuscript.

Comment 4: "Sample size justification is absent—was power calculated for detecting sensitivity differences?”

Response 4: A sample size justification has been added (lines 133-151).

Comment 5: "Please expand the methods to include a flow diagram of the protocol and define "new mass" explicitly (e.g., absent on prior imaging within 1 year).”

Response 5: Thank you for the recommendation. The flow diagram has been added in the Methods section as Figure 1.

Comment 6: "If applicable report inter-rater reliability for BI-RADS assignments if multiple radiologists were involved. This will enhance reproducibility.”

Response 6: Unfortunately since the dataset does not identify the specific radiologists for each assignment, calculating inter-rater reliability is not possible. This limitation has been noted in the manuscript (lines 312-313).

Comment 7: "Table 1 shows gravidity differences (p<0.001), but the text misinterprets; higher gravidity (≥5) is more common in malignant cases (34.81% vs. 14.56%), yet you state "fewer pregnancies" for benign—correct this.”

Response 7: We made the necessary amendments (line 176).

Comment 8: "No confidence intervals (CIs) for diagnostic metrics, limiting precision assessment. Please add 95% CIs to all metrics in Table 3.”

Response 8: We added 95% CIs to all metrics in Table 3 (Table 3).

Comment 9: "Please update to include 2024-2025 publications.”

Response 9: This has been done, references from 2024 and 2025 have been used and included (Reference number: 12, 13, and 18).

Sincerely,

Dr. Amirhossein Eskandari

Attachments
Attachment
Submitted filename: Point by point Response.docx
Decision Letter - Amirreza Khalaji, Editor

What Is the Significance of A New Breast Mass in Women Aged 40 or Above? A Cross-sectional Study

PONE-D-25-37061R1

Dear Dr. Amirhossein Eskandari,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Amirreza Khalaji

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I only suggest revising in typos, punctuation, and double spaces as seen.The manuscript now looks better for acceptance. This manuscript will definitely add valuable impact on diagnostic decision-making and future patient outcomes despite the existence of some study limitations.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Amirreza Khalaji, Editor

PONE-D-25-37061R1

PLOS One

Dear Dr. Eskandari,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Amirreza Khalaji

Academic Editor

PLOS One

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .